Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification

Colaboración

Año: 2017

Sepulveda-Sanchez, JM; Vaz, MA; Balana, C; Gil-Gil, M; Reynes, G; Gallego, O; Martinez-Garcia, M; Vicente, E; Quindos, M; Luque, R; Ramos, A; Ruano, Y; Perez-Segura, P; Benavides, M; Sanchez-Gomez, P; Hernandez-Lain, A

Título: NEURO-ONCOLOGY

• D1